Downregulation of trefoil factor‑3 expression in the rectum is associated with the development of ulcerative colitis‑associated cancer

Kondo,Satoru; Araki,Toshimitsu; Toiyama,Yuji; Tanaka,Koji; Kawamura,Mikio; Okugawa,Yoshinaga; Okita,Yoshiki; Saigusa,Susumu; Inoue,Yasuhiro; Uchida,Keiichi; Mohri,Yasuhiko; Kusunoki,Masato

doi:10.3892/ol.2018.9120

Downregulation of trefoil factor‑3 expression in the rectum is associated with the development of ulcerative colitis‑associated cancer

Authors:
- Satoru Kondo
- Toshimitsu Araki
- Yuji Toiyama
- Koji Tanaka
- Mikio Kawamura
- Yoshinaga Okugawa
- Yoshiki Okita
- Susumu Saigusa
- Yasuhiro Inoue
- Keiichi Uchida
- Yasuhiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: July 10, 2018 https://doi.org/10.3892/ol.2018.9120
Pages: 3658-3664
Copyright: © Kondo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diagnostic markers facilitate more selective screening and treatment strategies for ulcerative colitis (UC)‑associated cancer (UCAC). The expression of trefoil factor‑3 (TFF3), which is involved in mucosal protection and repair in the gastrointestinal tract, was analyzed and its significance for UCAC was evaluated. A total of 145 patients with UC who underwent proctocolectomies were enrolled, including 15 patients (10.8%) with UCAC. TFF3 expression in the rectal mucosa and in cancer cells was assessed using immunohistochemistry, and the expression in UCAC and sporadic colorectal cancer was compared. Analyzing the mucinous granules of goblet cells located in crypts revealed that the non‑cancerous rectal mucosa of patients with UCAC had significantly lower mean TFF3 staining scores compared with patients with UC without UCAC or patients with sporadic cancer. TFF3 staining score was revealed to be an independent predictor of UCAC development. These results indicated that low TFF3 expression in the rectal mucosa was associated with the development of UCAC. Thus, TFF3 expression in the rectal mucosa may be a useful biomarker for monitoring patients with UC.

View Figures

View References

1	de Dombal FT, Burch PR and Watkinson G: Aetiology of ulcerative colitis. Gut. 10:270–277. 1969. View Article : Google Scholar : PubMed/NCBI
2	Cho JH and Brant SR: Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 140:1704–1712. 2011. View Article : Google Scholar : PubMed/NCBI
3	Thompson AI and Lees CW: Genetics of ulcerative colitis. Inflamm Bowel Dis. 17:831–848. 2011. View Article : Google Scholar : PubMed/NCBI
4	Danese S and Fiocchi C: Ulcerative colitis. N Engl J Med. 365:1713–1725. 2011. View Article : Google Scholar : PubMed/NCBI
5	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
6	Munkholm P: Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 18 Suppl 2:S1–S5. 2003. View Article : Google Scholar
7	Jess T, Rungoe C and Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 10:639–645. 2012. View Article : Google Scholar : PubMed/NCBI
8	Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML and Haggitt RC: Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 105:418–424. 1993. View Article : Google Scholar : PubMed/NCBI
9	Vleggaar FP, Lutgens MW and Claessen MM: Review article: The relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 26 Suppl 2:S47–S52. 2007. View Article : Google Scholar
10	Jess T, Frisch M and Simonsen J: Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 11:43–48. 2013. View Article : Google Scholar : PubMed/NCBI
11	Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD and Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 143:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
12	Poulsom R and Wright NA: Trefoil peptides: A newly recognized family of epithelial mucin-associated molecules. Am J Physiol. 265:G205–G213. 1993.PubMed/NCBI
13	Thim L: Trefoil peptides: A new family of gastrointestinal molecules. Digestion. 55:353–360. 1994. View Article : Google Scholar : PubMed/NCBI
14	Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C, et al: Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology. 104:12–20. 1993. View Article : Google Scholar : PubMed/NCBI
15	Madsen J, Nielsen O, Tornøe I, Thim L and Holmskov U: Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar : PubMed/NCBI
16	Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK and Wang TC: TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest. 109:193–204. 2002. View Article : Google Scholar : PubMed/NCBI
17	Babyatsky MW, deBeaumont M, Thim L and Podolsky DK: Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology. 110:489–497. 1996. View Article : Google Scholar : PubMed/NCBI
18	Taupin D and Podolsky DK: Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kinoshita K, Taupin DR, Itoh H and Podolsky DK: Distinct pathways of cell migration and antiapoptotic response to epithelial injury: Structure-function analysis of human intestinal trefoil factor. Mol Cell Biol. 20:4680–4690. 2000. View Article : Google Scholar : PubMed/NCBI
20	Dignass A, Lynch-Devaney K, Kindon H, Thim L and Podolsky DK: Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest. 94:376–383. 1994. View Article : Google Scholar : PubMed/NCBI
21	Kirikoshi H and Katoh M: Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol. 21:655–659. 2002.PubMed/NCBI
22	Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, Ng EK, Chung SC, Malfertheiner P and Sung JJ: Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 197:582–588. 2002. View Article : Google Scholar : PubMed/NCBI
23	Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, Yamamura Y, Chen A and Itzkowitz S: Intestinal trefoil factor: A marker of poor prognosis in gastric carcinoma. Clin Cancer Res. 8:1092–1099. 2002.PubMed/NCBI
24	Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, Kubota H and Nagasue N: Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005. View Article : Google Scholar : PubMed/NCBI
25	Morito K, Nakamura J, Kitajima Y, Kai K, Tanaka T, Kubo H, Miyake S and Noshiro H: The value of trefoil factor 3 expression in predicting the lon-gterm outcome and early recurrence of colorectal cancer. Int J Oncol. 46:563–568. 2015. View Article : Google Scholar : PubMed/NCBI
26	Huang YG, Li YF, Wang LP and Zhang Y: Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380. 2013. View Article : Google Scholar : PubMed/NCBI
27	Southgate HW: Note on preparing mucicarmine. J Pathol Bacteriol. 30:7291927. View Article : Google Scholar
28	Sobin LH and Wittekind Ch: UICC TNM Classification of Malignant Tumors. 6th edition. John Wiley and Sons; New York: pp. 52–56. 2002
29	Xiao L, Liu YP, Xiao CX, Ren JL and Guleng B: Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol. 14:262014. View Article : Google Scholar : PubMed/NCBI
30	John R, El-Rouby NM, Tomasetto C, Rio MC and Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol. 22:743–751. 2007.PubMed/NCBI
31	Gu J, Zheng L, Zhang L, Chen S, Zhu M, Li X and Wang Y: TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour Biol. 36:3001–3007. 2015. View Article : Google Scholar : PubMed/NCBI
32	Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T and Lobie PE: Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 16:4292014. View Article : Google Scholar : PubMed/NCBI
33	Garraway IP, Seligson D, Said J, Horvath S and Reiter RE: Trefoil factor 3 is overexpressed in human prostate cancer. Prostate. 61:209–214. 2004. View Article : Google Scholar : PubMed/NCBI
34	Neutra M and Leblond CP: Synthesis of the carbohydrate of mucus in the golgi complex as shown by electron microscope radioautography of goblet cells from rats injected with glucose-H3. J Cell Biol. 30:119–136. 1996. View Article : Google Scholar
35	Suemori S, Lynch-Devaney K and Podolsky DK: Identification and characterization of rat intestinal trefoil factor: Tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci USA. 88:11017–11021. 1991. View Article : Google Scholar : PubMed/NCBI
36	Taupin D, Ooi K, Yeomans N and Giraud A: Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest. 75:25–32. 1996.PubMed/NCBI
37	Sands BE and Podolsky DK: The trefoil peptide family. Annu Rev Physiol. 58:253–273. 1996. View Article : Google Scholar : PubMed/NCBI
38	Mashimo H, Wu DC, Podolsky DK and Fishman MC: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 274:262–265. 1996. View Article : Google Scholar : PubMed/NCBI
39	Ullman T, Odze R and Farraye FA: Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis. 15:630–638. 2009. View Article : Google Scholar : PubMed/NCBI
40	Itzkowitz SH and Present DH: Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group: Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 11:314–321. 2005. View Article : Google Scholar : PubMed/NCBI
41	Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC and Forbes A: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 130:1030–1038. 2006. View Article : Google Scholar : PubMed/NCBI
42	Kornbluth A and Sachar DB: Practice Parameters Committee of the American College of Gastroenterology: Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 105:501–523. 2010. View Article : Google Scholar : PubMed/NCBI
43	Collins PD, Mpofu C, Watson AJ and Rhodes JM: Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 19:CD0002792006.
44	Hata K, Watanabe T, Kazama S, Suzuki K, Shinozaki M, Yokoyama T, Matsuda K, Muto T and Nagawa H: Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: Results of a 23-year surveillance programme in the Japanese population. Br J Cancer. 89:1232–1236. 2003. View Article : Google Scholar : PubMed/NCBI
45	Rex DK: Preventing colorectal cancer and cancer mortality with colonoscopy: What we know and what we don't know. Endoscopy. 42:320–323. 2010. View Article : Google Scholar : PubMed/NCBI
46	Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP and Brentnall TA: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Physiol. 162:665–672. 2003.
47	Neumann H, Vieth M, Langner C, Neurath MF and Mudter J: Cancer risk in IBD: How to diagnose and how to manage DALM and ALM. World J Gastroenterol. 17:3184–3191. 2011.PubMed/NCBI
48	Chai H and Brown RE: Field effect in cancer-an update. Ann Clin Lab Sci. 39:331–337. 2009.PubMed/NCBI
49	Slaughter DP, Southwick HW and Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 6:963–968. 1953. View Article : Google Scholar : PubMed/NCBI
50	Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, et al: Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer. 10:134–141. 2011. View Article : Google Scholar : PubMed/NCBI
51	Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M and Porschen R: Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 58:3942–3945. 1998.PubMed/NCBI
52	Risques RA, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, et al: Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 71:1669–1679. 2011. View Article : Google Scholar : PubMed/NCBI